drugset
drugset / Trial / NCT02950922

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

NCT02950922 ↗

Phase 2 Completed 157 enrolled Dermavant Sciences GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, randomized, vehicle-controlled, double-blind Phase 2 study in adults and adolescent subjects with mild to moderate atopic dermatitis.

Timeline

Start
2016-11
Primary completion
2017-07-03
Completion
2017-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject LOTAMILAST Small molecule 0.2 % Topical
Subject LOTAMILAST Small molecule 0.5 % Topical

Indications

atopic eczema